Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Antipsychotics in Alzheimer’s Disease: Current Status and Therapeutic Alternatives

Author(s): Maria Paula Maziero*, Natalia P. Rocha and Antonio L. Teixeira

Volume 20, Issue 10, 2023

Published on: 22 February, 2024

Page: [682 - 691] Pages: 10

DOI: 10.2174/0115672050287534240215052417

Price: $65

Abstract

Psychosis and hyperactive behaviors, such as agitation and wandering, affect a significant proportion of patients with Alzheimer’s disease (AD). These symptoms are often treated with antipsychotics, usually in an off-label approach. This mini-review provides an updated perspective on the pharmacological approach for the neuropsychiatric symptoms (NPS) in AD. The results of new studies have provided a better understanding of AD-related NPS management, but high-quality evidence still needs to be obtained. Herein, we argue for a more cautious approach to the use of antipsychotics in AD and highlight the importance of exploring alternative treatments for NPS. By doing so, we can ensure that patients with AD receive optimal care that is both effective and safe.

« Previous Next »
[1]
Gerlach, L.B.; Kales, H.C. Managing behavioral and psychological symptoms of dementia. Psychiatr. Clin. North Am., 2018, 41(1), 127-139.
[http://dx.doi.org/10.1016/j.psc.2017.10.010] [PMID: 29412841]
[2]
Ismail, Z.; Creese, B.; Aarsland, D.; Kales, H.C.; Lyketsos, C.G.; Sweet, R.A.; Ballard, C. Psychosis in Alzheimer disease — mechanisms, genetics and therapeutic opportunities. Nat. Rev. Neurol., 2022, 18(3), 131-144.
[http://dx.doi.org/10.1038/s41582-021-00597-3] [PMID: 34983978]
[3]
Ballard, C.G.; Gauthier, S.; Cummings, J.L.; Brodaty, H.; Grossberg, G.T.; Robert, P.; Lyketsos, C.G. Management of agitation and aggression associated with Alzheimer disease. Nat. Rev. Neurol., 2009, 5(5), 245-255.
[http://dx.doi.org/10.1038/nrneurol.2009.39] [PMID: 19488082]
[4]
Creese, B.; Da Silva, M.V.; Johar, I.; Ballard, C. The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer’s disease. Expert Rev. Neurother., 2018, 18(6), 461-467.
[http://dx.doi.org/10.1080/14737175.2018.1476140] [PMID: 29764230]
[5]
Yunusa, I.; Alsumali, A.; Garba, A.E.; Regestein, Q.R.; Eguale, T. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia. JAMA Netw. Open, 2019, 2(3), e190828.
[http://dx.doi.org/10.1001/jamanetworkopen.2019.0828] [PMID: 30901041]
[6]
Rubino, A.; Sanon, M.; Ganz, M.L.; Simpson, A.; Fenton, M.C.; Verma, S.; Hartry, A.; Baker, R.A.; Duffy, R.A.; Gwin, K.; Fillit, H. Association of the US food and drug administration antipsychotic drug boxed warning with medication use and health outcomes in elderly patients with dementia. JAMA Netw. Open, 2020, 3(4), e203630.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.3630] [PMID: 32343351]
[7]
Rogowska, M.; Thornton, M.; Creese, B.; Velayudhan, L.; Aarsland, D.; Ballard, C.; Tsamakis, K.; Stewart, R.; Mueller, C. Implications of adverse outcomes associated with antipsychotics in older patients with dementia: A 2011–2022 Update. Drugs Aging, 2023, 40(1), 21-32.
[http://dx.doi.org/10.1007/s40266-022-00992-5] [PMID: 36513918]
[8]
Mueller, C.; John, C.; Perera, G.; Aarsland, D.; Ballard, C.; Stewart, R. Antipsychotic use in dementia: The relationship between neuropsychiatric symptom profiles and adverse outcomes. Eur. J. Epidemiol., 2021, 36(1), 89-101.
[http://dx.doi.org/10.1007/s10654-020-00643-2] [PMID: 32415541]
[9]
Ropacki, S.A.; Jeste, D.V. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am. J. Psychiatry, 2005, 162(11), 2022-2030.
[http://dx.doi.org/10.1176/appi.ajp.162.11.2022] [PMID: 16263838]
[10]
van der Linde, R.M.; Dening, T.; Stephan, B.C.M.; Prina, A.M.; Evans, E.; Brayne, C. Longitudinal course of behavioural and psychological symptoms of dementia: Systematic review. Br. J. Psychiatry, 2016, 209(5), 366-377.
[http://dx.doi.org/10.1192/bjp.bp.114.148403] [PMID: 27491532]
[11]
Cook, S.E.; Miyahara, S.; Bacanu, S.A.; Perez-Madriñan, G.; Lopez, O.L.; Kaufer, D.I.; Nimgaonkar, V.L.; Wisniewski, S.R.; DeKosky, S.T.; Sweet, R.A. Psychotic symptoms in Alzheimer disease: Evidence for subtypes. Am. J. Geriatr. Psychiatry, 2003, 11(4), 406-413.
[http://dx.doi.org/10.1097/00019442-200307000-00003] [PMID: 12837669]
[12]
Pearce, D.; Gould, R.L.; Roughley, M.; Reynolds, G.; Ward, E.V.; Bhome, R.; Reeves, S. Paranoid and misidentification subtypes of psychosis in dementia. Neurosci. Biobehav. Rev., 2022, 134, 104529.
[http://dx.doi.org/10.1016/j.neubiorev.2022.104529] [PMID: 35032536]
[13]
Fraser, J.A. Hallucinations, visual and auditory. In: Encyclopedia of the Neurological Sciences, 2nd ed; Aminoff, M.J.; Daroff, R.B., Eds.; Academic Press: Oxford, 2014; pp. 500-501.
[http://dx.doi.org/10.1016/B978-0-12-385157-4.00135-4]
[14]
Zhao, Q.F.; Tan, L.; Wang, H.F.; Jiang, T.; Tan, M.S.; Tan, L.; Xu, W.; Li, J.Q.; Wang, J.; Lai, T.J.; Yu, J.T. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis. J. Affect. Disord., 2016, 190, 264-271.
[http://dx.doi.org/10.1016/j.jad.2015.09.069] [PMID: 26540080]
[15]
Wilson, R.S.; Gilley, D.W.; Bennett, D.A.; Beckett, L.A.; Evans, D.A. Hallucinations, delusions, and cognitive decline in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry, 2000, 69(2), 172-177.
[http://dx.doi.org/10.1136/jnnp.69.2.172] [PMID: 10896689]
[16]
Linszen, M.M.J.; Lemstra, A.W.; Dauwan, M.; Brouwer, R.M.; Scheltens, P.; Sommer, I.E.C. Understanding hallucinations in probable Alzheimer’s disease: Very low prevalence rates in a tertiary memory clinic. Alzheimers Dement., 2018, 10(1), 358-362.
[http://dx.doi.org/10.1016/j.dadm.2018.03.005] [PMID: 30014034]
[17]
Senanarong, V.; Cummings, J.L.; Fairbanks, L.; Mega, M.; Masterman, D.M.; O’Connor, S.M.; Strickland, T.L. Agitation in Alzheimer’s disease is a manifestation of frontal lobe dysfunction. Dement. Geriatr. Cogn. Disord., 2004, 17(1-2), 14-20.
[http://dx.doi.org/10.1159/000074080] [PMID: 14560060]
[18]
Wolf, MU; Goldberg, Y; Freedman, M Aggression and agitation in dementia. Continuum, 2018, 783-803.
[http://dx.doi.org/10.1212/CON.0000000000000605]
[19]
Eikelboom, W.S.; Pan, M.; Ossenkoppele, R.; Coesmans, M.; Gatchel, J.R.; Ismail, Z.; Lanctôt, K.L.; Fischer, C.E.; Mortby, M.E.; van den Berg, E.; Papma, J.M. Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: A meta-analysis. Alzheimers Res. Ther., 2022, 14(1), 48.
[http://dx.doi.org/10.1186/s13195-022-00991-z] [PMID: 35379344]
[20]
Peters, M.E.; Schwartz, S.; Han, D.; Rabins, P.V.; Steinberg, M.; Tschanz, J.T.; Lyketsos, C.G. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: The cache county dementia progression study. Am. J. Psychiatry, 2015, 172(5), 460-465.
[http://dx.doi.org/10.1176/appi.ajp.2014.14040480] [PMID: 25585033]
[21]
Nielsen, R.E.; Lolk, A.; Rodrigo-Domingo, M.; Valentin, J.B.; Andersen, K. Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer’s dementia. Eur. Psychiatry, 2017, 42, 14-23.
[http://dx.doi.org/10.1016/j.eurpsy.2016.11.013] [PMID: 28199869]
[22]
Kirkham, J.; Sherman, C.; Velkers, C.; Maxwell, C.; Gill, S.; Rochon, P.; Seitz, D. Antipsychotic use in dementia. Can. J. Psychiatry, 2017, 62(3), 170-181.
[http://dx.doi.org/10.1177/0706743716673321] [PMID: 28212496]
[23]
Yunusa, I.; Rashid, N.; Abler, V.; Rajagopalan, K. Comparative efficacy, safety, tolerability, and effectiveness of antipsychotics in the treatment of dementia-related psychosis (drp): A systematic literature review. J. Prev. Alzheimers Dis., 2021, 8(4), 520-533.
[PMID: 34585228]
[24]
Mühlbauer, V.; Möhler, R.; Dichter, M.N.; Zuidema, S.U.; Köpke, S.; Luijendijk, H.J. Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia. Cochrane Database Syst. Rev., 2021, 12(12), CD013304.
[PMID: 34918337]
[25]
Lenzer, J. FDA warns about using antipsychotic drugs for dementia. BMJ, 2005, 330(7497), 922.4.
[http://dx.doi.org/10.1136/bmj.330.7497.922-c] [PMID: 15845964]
[26]
Dorsey, E.R.; Rabbani, A.; Gallagher, S.A.; Conti, R.M.; Alexander, G.C. Impact of FDA black box advisory on antipsychotic medication use. Arch. Intern. Med., 2010, 170(1), 96-103.
[http://dx.doi.org/10.1001/archinternmed.2009.456] [PMID: 20065205]
[27]
Gill, S.S.; Bronskill, S.E.; Normand, S.L.T.; Anderson, G.M.; Sykora, K.; Lam, K.; Bell, C.M.; Lee, P.E.; Fischer, H.D.; Herrmann, N.; Gurwitz, J.H.; Rochon, P.A. Antipsychotic drug use and mortality in older adults with dementia. Ann. Intern. Med., 2007, 146(11), 775-786.
[http://dx.doi.org/10.7326/0003-4819-146-11-200706050-00006] [PMID: 17548409]
[28]
Watt, J.A.; Goodarzi, Z.; Veroniki, A.A.; Nincic, V.; Khan, P.A.; Ghassemi, M.; Thompson, Y.; Lai, Y.; Treister, V.; Tricco, A.C.; Straus, S.E. Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: A systematic review and network meta-analysis. BMC Geriatr., 2020, 20(1), 212.
[http://dx.doi.org/10.1186/s12877-020-01607-7] [PMID: 32546202]
[29]
Zhai, Y.; Yin, S.; Zhang, D. Association between antipsychotic drugs and mortality in older persons with alzheimer’s disease: A systematic review and meta-analysis. J. Alzheimers Dis., 2016, 52(2), 631-639.
[http://dx.doi.org/10.3233/JAD-151207] [PMID: 27031490]
[30]
Koponen, M.; Rajamaki, B.; Lavikainen, P.; Bell, J.S.; Taipale, H.; Tanskanen, A.; Hartikainen, S.; Tolppanen, A.M. Antipsychotic use and risk of stroke among community-dwelling people with alzheimer’s disease. J. Am. Med. Dir. Assoc., 2022, 23(6), 1059-1065.e4.
[http://dx.doi.org/10.1016/j.jamda.2021.09.036] [PMID: 34717887]
[31]
Harrison, S.L.; Sluggett, J.K.; Lang, C.; Whitehead, C.; Crotty, M.; Corlis, M.; Wesselingh, S.; Inacio, M.C. Initiation of antipsychotics after moving to residential aged care facilities and mortality: A national cohort study. Aging Clin. Exp. Res., 2021, 33(1), 95-104.
[http://dx.doi.org/10.1007/s40520-020-01518-y] [PMID: 32162240]
[32]
Nørgaard, A.; Jensen-Dahm, C.; Wimberley, T.; Svendsen, J.H.; Ishtiak-Ahmed, K.; Laursen, T.M.; Waldemar, G.; Gasse, C. Effect of antipsychotics on mortality risk in patients with dementia with and without comorbidities. J. Am. Geriatr. Soc., 2022, 70(4), 1169-1179.
[http://dx.doi.org/10.1111/jgs.17623] [PMID: 35029305]
[33]
Goff, D.C., Jr; Lloyd-Jones, D.M.; Bennett, G.; Coady, S.; D’Agostino, R.B.; Gibbons, R.; Greenland, P.; Lackland, D.T.; Levy, D.; O’Donnell, C.J.; Robinson, J.G.; Schwartz, J.S.; Shero, S.T.; Smith, S.C., Jr; Sorlie, P.; Stone, N.J.; Wilson, P.W.F.; Jordan, H.S.; Nevo, L.; Wnek, J.; Anderson, J.L.; Halperin, J.L.; Albert, N.M.; Bozkurt, B.; Brindis, R.G.; Curtis, L.H.; DeMets, D.; Hochman, J.S.; Kovacs, R.J.; Ohman, E.M.; Pressler, S.J.; Sellke, F.W.; Shen, W.K.; Smith, S.C., Jr; Tomaselli, G.F. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation, 2014, 129(25_suppl_2)(Suppl. 2), S49-S73.
[http://dx.doi.org/10.1161/01.cir.0000437741.48606.98] [PMID: 24222018]
[34]
Burns, P.B.; Rohrich, R.J.; Chung, K.C. The levels of evidence and their role in evidence-based medicine. Plast. Reconstr. Surg., 2011, 128(1), 305-310.
[http://dx.doi.org/10.1097/PRS.0b013e318219c171] [PMID: 21701348]
[35]
Reus, V.I.; Fochtmann, L.J.; Eyler, A.E.; Hilty, D.M.; Horvitz-Lennon, M.; Jibson, M.D.; Lopez, O.L.; Mahoney, J.; Pasic, J.; Tan, Z.S.; Wills, C.D.; Rhoads, R.; Yager, J. The american psychiatric association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Focus Am. Psychiatr. Publ., 2017, 15(1), 81-84.
[http://dx.doi.org/10.1176/appi.focus.15107] [PMID: 31997967]
[36]
Huang, Y.Y.; Teng, T.; Shen, X.N.; Chen, S.D.; Wang, R.Z.; Zhang, R.Q.; Dou, K.X.; Zhong, X.L.; Wang, J.; Chen, K.L.; Zhao, Q.H.; Tan, L.; Dong, Q.; Zhou, X.Y.; Yu, J.T. Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis. Ageing Res. Rev., 2022, 75, 101568.
[http://dx.doi.org/10.1016/j.arr.2022.101568] [PMID: 35051646]
[37]
Chen, A.; Copeli, F.; Metzger, E.; Cloutier, A.; Osser, D.N. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia. Psychiatry Res., 2021, 295, 113641.
[http://dx.doi.org/10.1016/j.psychres.2020.113641] [PMID: 33340800]
[38]
Li, D.D.; Zhang, Y.H.; Zhang, W.; Zhao, P. Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of alzheimer’s disease. Front. Neurosci., 2019, 13, 472.
[http://dx.doi.org/10.3389/fnins.2019.00472] [PMID: 31156366]
[39]
d’Angremont, E.; Begemann, M.J.H.; van Laar, T.; Sommer, I.E.C. Cholinesterase inhibitors for treatment of psychotic symptoms in alzheimer disease and parkinson disease. JAMA Neurol., 2023, 80(8), 813-823.
[http://dx.doi.org/10.1001/jamaneurol.2023.1835] [PMID: 37358841]
[40]
Andrade, C. Cholinesterase inhibitors for delusions and hallucinations in Alzheimer disease and Parkinson disease: questionably significant benefits. J. Clin. Psychiatr., 2023, 84(4), 23.
[41]
Kongpakwattana, K.; Sawangjit, R.; Tawankanjanachot, I.; Bell, J.S.; Hilmer, S.N.; Chaiyakunapruk, N. Pharmacological treatments for alleviating agitation in dementia: A systematic review and network meta-analysis. Br. J. Clin. Pharmacol., 2018, 84(7), 1445-1456.
[http://dx.doi.org/10.1111/bcp.13604] [PMID: 29637593]
[42]
Hsu, T.W.; Stubbs, B.; Liang, C.S.; Chen, T.Y.; Yeh, T.C.; Pan, C.C.; Chu, C.S. Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: A systematic review and meta-analysis. Ageing Res. Rev., 2021, 69, 101362.
[http://dx.doi.org/10.1016/j.arr.2021.101362] [PMID: 34000464]
[43]
Zhang, J.; Zheng, X.; Zhao, Z. A systematic review and meta-analysis on the efficacy outcomes of selective serotonin reuptake inhibitors in depression in Alzheimer’s disease. BMC Neurol., 2023, 23(1), 210.
[http://dx.doi.org/10.1186/s12883-023-03191-w] [PMID: 37259037]
[44]
Peskind, E.R.; Tsuang, D.W.; Bonner, L.T.; Pascualy, M.; Riekse, R.G.; Snowden, M.B.; Thomas, R.; Raskind, M.A. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: A placebo-controlled study. Alzheimer Dis. Assoc. Disord., 2005, 19(1), 23-28.
[http://dx.doi.org/10.1097/01.wad.0000155067.16313.5e] [PMID: 15764868]
[45]
Tampi, RR; Tampi, DJ; Farheen, SA; Ochije, SI; Joshi, P Propranolol for the management of behavioural and psychological symptoms of dementia. Drugs Context, 2022, 11, 8-3.
[http://dx.doi.org/10.7573/dic.2022-8-3]
[46]
Davies, S.J.C.; Burhan, A.M.; Kim, D.; Gerretsen, P.; Graff-Guerrero, A.; Woo, V.L.; Kumar, S.; Colman, S.; Pollock, B.G.; Mulsant, B.H.; Rajji, T.K. Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. J. Psychopharmacol., 2018, 32(5), 509-523.
[http://dx.doi.org/10.1177/0269881117744996] [PMID: 29338602]
[47]
Tampi, RR; Tampi, DJ; Farheen, SA; Adnan, M; Dasarathy, D Prazosin for the management of behavioural and psychological symptoms of dementia. Drugs Context, 2022, 11, 3-3.
[http://dx.doi.org/10.7573/dic.2022-3-3]
[48]
van den Berg, J.F.; Kruithof, H.C.; Kok, R.M.; Verwijk, E.; Spaans, H.P. Electroconvulsive therapy for agitation and aggression in dementia: A systematic review. Am. J. Geriatr. Psychiatry, 2018, 26(4), 419-434.
[http://dx.doi.org/10.1016/j.jagp.2017.09.023] [PMID: 29107460]
[49]
van Diermen, L.; van den Ameele, S.; Kamperman, A.M.; Sabbe, B.C.G.; Vermeulen, T.; Schrijvers, D.; Birkenhäger, T.K. Prediction of electroconvulsive therapy response and remission in major depression: Meta-analysis. Br. J. Psychiatry, 2018, 212(2), 71-80.
[http://dx.doi.org/10.1192/bjp.2017.28] [PMID: 29436330]
[50]
Kumar, S.; Mulsant, B.H.; Liu, A.Y.; Blumberger, D.M.; Daskalakis, Z.J.; Rajji, T.K. Systematic review of cognitive effects of electroconvulsive therapy in late-life depression. Am. J. Geriatr. Psychiatry, 2016, 24(7), 547-565.
[http://dx.doi.org/10.1016/j.jagp.2016.02.053] [PMID: 27067067]
[51]
Hacksell, U.; Burstein, E.S.; McFarland, K.; Mills, R.G.; Williams, H. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis. Neurochem. Res., 2014, 39(10), 2008-2017.
[http://dx.doi.org/10.1007/s11064-014-1293-3] [PMID: 24682754]
[52]
Cummings, J.L.; Devanand, D.P.; Stahl, S.M. Dementia-related psychosis and the potential role for pimavanserin. CNS Spectr., 2022, 27(1), 7-15.
[http://dx.doi.org/10.1017/S1092852920001765] [PMID: 32811586]
[53]
Tariot, P.N.; Cummings, J.L.; Soto-Martin, M.E.; Ballard, C.; Erten-Lyons, D.; Sultzer, D.L.; Devanand, D.P.; Weintraub, D.; McEvoy, B.; Youakim, J.M.; Stankovic, S.; Foff, E.P. Trial of pimavanserin in dementia-related psychosis. N. Engl. J. Med., 2021, 385(4), 309-319.
[http://dx.doi.org/10.1056/NEJMoa2034634] [PMID: 34289275]
[54]
Acadia pharmaceuticals [internet [cited 2024 jan 9 acadia pharmaceuticals receives complete response letter from u.s. fda for supplemental new drug application for pimavanserin for the treatment of hallucinations and delusions associated with alzheimer’s disease psychosis. Available from: https://acadia.com/media/news-releases/acadia-pharmaceuticals-receives-complete-response-letter-from-u-s-fda-for-supplemental-new-drug-application-for-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-alzheime/
[55]
Srinivasan, S.; Tampi, R.R.; Balaram, K.; Kapoor, A. Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review. World J. Psychiatry, 2020, 10(7), 162-174.
[http://dx.doi.org/10.5498/wjp.v10.i7.162] [PMID: 32844093]
[56]
Hammond, F.M.; Alexander, D.N.; Cutler, A.J.; D’Amico, S.; Doody, R.S.; Sauve, W.; Zorowitz, R.D.; Davis, C.S.; Shin, P.; Ledon, F.; Yonan, C.; Formella, A.E.; Siffert, J. PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurol., 2016, 16(1), 89.
[http://dx.doi.org/10.1186/s12883-016-0609-0] [PMID: 27276999]
[57]
Ahmed, A.; Simmons, Z. Pseudobulbar affect: Prevalence and management. Ther. Clin. Risk Manag., 2013, 9, 483-489.
[PMID: 24348042]
[58]
Fralick, M.; Sacks, C.A.; Kesselheim, A.S. Assessment of off-label prescribing compared with fda-approved treatment with combined dextromethorphan and quinidine in 2 commercial insurance databases. JAMA Intern. Med., 2018, 178(9), 1240.
[PMID: 30039158]
[59]
Khoury, R. Deuterated dextromethorphan/quinidine for agitation in Alzheimer’s disease. Neural Regen. Res., 2022, 17(5), 1013-1014.
[http://dx.doi.org/10.4103/1673-5374.324842] [PMID: 34558525]
[60]
Cummings, J.L.; Lyketsos, C.G.; Peskind, E.R.; Porsteinsson, A.P.; Mintzer, J.E.; Scharre, D.W.; De La Gandara, J.E.; Agronin, M.; Davis, C.S.; Nguyen, U.; Shin, P.; Tariot, P.N.; Siffert, J. Effect of dextromethorphan-quinidine on agitation in patients with alzheimer disease dementia. JAMA, 2015, 314(12), 1242-1254.
[http://dx.doi.org/10.1001/jama.2015.10214] [PMID: 26393847]
[61]
Harris, E. FDA greenlights first drug for agitation related to alzheimer disease. JAMA, 2023, 329(22), 1907.
[http://dx.doi.org/10.1001/jama.2023.9153] [PMID: 37223961]
[62]
Correll, C.U.; Skuban, A.; Ouyang, J.; Hobart, M.; Pfister, S.; McQuade, R.D.; Nyilas, M.; Carson, W.H.; Sanchez, R.; Eriksson, H. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry, 2015, 172(9), 870-880.
[http://dx.doi.org/10.1176/appi.ajp.2015.14101275] [PMID: 25882325]
[63]
Yoon, S.; Jeon, S.W.; Ko, Y.H.; Patkar, A.A.; Masand, P.S.; Pae, C.U.; Han, C. Adjunctive brexpiprazole as a novel effective strategy for treating major depressive disorder. J. Clin. Psychopharmacol., 2017, 37(1), 46-53.
[http://dx.doi.org/10.1097/JCP.0000000000000622] [PMID: 27941419]
[64]
Grossberg, G.T.; Kohegyi, E.; Mergel, V.; Josiassen, M.K.; Meulien, D.; Hobart, M.; Slomkowski, M.; Baker, R.A.; McQuade, R.D.; Cummings, J.L. Efficacy and safety of brexpiprazole for the treatment of agitation in alzheimer’s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am. J. Geriatr. Psychiatry, 2020, 28(4), 383-400.
[http://dx.doi.org/10.1016/j.jagp.2019.09.009] [PMID: 31708380]
[65]
Hobart, M.; Zhang, P.; Skuban, A.; Brewer, C.; Hefting, N.; Sanchez, R.; McQuade, R.D. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder. J. Clin. Psychopharmacol., 2019, 39(3), 203-209.
[http://dx.doi.org/10.1097/JCP.0000000000001034] [PMID: 30946704]
[66]
Diefenderfer, L.A.; Iuppa, C. Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder. Ment. Health Clin., 2017, 7(5), 207-212.
[http://dx.doi.org/10.9740/mhc.2017.09.207] [PMID: 29955525]
[67]
REXULTI® (brexpiprazole) | agitation associated with dementia due to alzheimer’s disease | dosing and titration. Available from: https://www.rexultihcp.com/aad/dosing
[68]
Stella, F.; Valiengo, L.C.L.; Paula, V.J.R.; Lima, C.A.M.; Forlenza, O.V. Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: A systematic review. Trends Psychiatry Psychother., 2021, 43(4), 243-255.
[http://dx.doi.org/10.47626/2237-6089-2021-0288] [PMID: 34374269]
[69]
Bahji, A.; Meyyappan, A.C.; Hawken, E.R. Cannabinoids for the neuropsychiatric symptoms of dementia: A systematic review and meta-analysis. Can. J. Psychiatry, 2020, 65(6), 365-376.
[http://dx.doi.org/10.1177/0706743719892717] [PMID: 31835954]
[70]
Kuharic, B.D.; Markovic, D.; Brkovic, T.; Kegalj, J.M.; Rubic, Z.; Vukasovic, V.A.; Jeroncic, A.; Puljak, L. Cannabinoids for the treatment of dementia. Cochrane Database Syst. Rev., 2021, 9(9), CD012820.
[PMID: 34532852]
[71]
Charernboon, T.; Lerthattasilp, T.; Supasitthumrong, T. Effectiveness of cannabinoids for treatment of dementia: A systematic review of randomized controlled trials. Clin. Gerontol., 2021, 44(1), 16-24.
[http://dx.doi.org/10.1080/07317115.2020.1742832] [PMID: 32186469]
[72]
Herrmann, N.; Ruthirakuhan, M.; Gallagher, D.; Verhoeff, N.P.L.G.; Kiss, A.; Black, S.E.; Lanctôt, K.L. Randomized placebo-controlled trial of nabilone for agitation in alzheimer’s disease. Am. J. Geriatr. Psychiatry, 2019, 27(11), 1161-1173.
[http://dx.doi.org/10.1016/j.jagp.2019.05.002] [PMID: 31182351]
[73]
Hillen, J.B.; Soulsby, N.; Alderman, C.; Caughey, G.E. Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: A systematic review. Ther. Adv. Drug Saf., 2019, 10
[http://dx.doi.org/10.1177/2042098619846993] [PMID: 31205674]
[74]
Paunescu, H.; Dima, L.; Ghita, I.; Coman, L.; Ifteni, P.I.; Fulga, I.; Coman, O.A. A systematic review of clinical studies on the effect of psychoactive cannabinoids in psychiatric conditions in alzheimer dementia. Am. J. Ther., 2020, 27(3), e249-e269.
[http://dx.doi.org/10.1097/MJT.0000000000001120] [PMID: 32118591]
[75]
Tripathi, P.N.; Srivastava, P.; Sharma, P.; Tripathi, M.K.; Seth, A.; Tripathi, A.; Rai, S.N.; Singh, S.P.; Shrivastava, S.K. Biphenyl-3-oxo-1,2,4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorg. Chem., 2019, 85, 82-96.
[http://dx.doi.org/10.1016/j.bioorg.2018.12.017] [PMID: 30605887]
[76]
Ramakrishna, K.; Nalla, L.V.; Naresh, D.; Venkateswarlu, K.; Viswanadh, M.K.; Nalluri, B.N.; Chakravarthy, G.; Duguluri, S.; Singh, P.; Rai, S.N.; Kumar, A.; Singh, V.; Singh, S.K. WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective. Diseases, 2023, 11(3), 89.
[http://dx.doi.org/10.3390/diseases11030089] [PMID: 37489441]
[77]
Rai, S.N.; Zahra, W.; Birla, H.; Singh, S.S.; Singh, S.P. Commentary: Mild endoplasmic reticulum stress ameliorates lpopolysaccharide-induced neuroinflammation and cognitive impairment via regulation of microglial polarization. Front. Aging Neurosci., 2018, 10, 192.
[http://dx.doi.org/10.3389/fnagi.2018.00192] [PMID: 29988480]
[78]
Srivastava, P.; Tripathi, P.N.; Sharma, P.; Rai, S.N.; Singh, S.P.; Srivastava, R.K.; Shankar, S.; Shrivastava, S.K. Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory. Eur. J. Med. Chem., 2019, 163, 116-135.
[http://dx.doi.org/10.1016/j.ejmech.2018.11.049] [PMID: 30503937]
[79]
Wijesinghe, R. A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics. Ment. Health Clin., 2016, 6(1), 21-27.
[http://dx.doi.org/10.9740/mhc.2016.01.021] [PMID: 29955443]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy